Meningeal immunity and “Interstitial” therapy: a new paradigm for immunotherapy in glioblastoma - Top-Institutions - MDSpire

Meningeal immunity and “Interstitial” therapy: a new paradigm for immunotherapy in glioblastoma

  • By

  • Hongan Fei

  • Xichao Wen

  • Wensong Wu

  • HaiPeng Liu

  • Haipeng Xie

  • Yan Wang

  • Kebin Zheng

  • Zhaomu Zeng

  • Zetong Bai

  • June 15, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, FL

    Key Differentiators

    • Oncology

  • #3

    Mass General Brigham Cancer Institute
    Mass General Brigham Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #4

    Northwestern University
    Northwestern University

    Chicago, IL

    Key Differentiators

    • Oncology

  • #5

    Columbia University Medical Center
    Columbia University Medical Center

    New York, NY

    Key Differentiators

    • Oncology

Original Source(s)

Meningeal immunity and “Interstitial” therapy: a new paradigm for immunotherapy in glioblastoma

  • by Hongan Fei, Xichao Wen, Wensong Wu, HaiPeng Liu, Haipeng Xie, Yan Wang, Kebin Zheng, Zhaomu Zeng, Zetong Bai

  • June 15, 2026

Related Content

Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial)

Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer

Correction: Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies – a comprehensive review